{"protocolSection": {"identificationModule": {"nctId": "NCT00882440", "orgStudyIdInfo": {"id": "0954-011"}, "secondaryIdInfos": [{"id": "MK0954-011"}, {"id": "2009_574"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)", "officialTitle": "A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954)"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1990-12"}, "primaryCompletionDateStruct": {"date": "1991-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "1992-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-14", "studyFirstSubmitQcDate": "2009-04-14", "studyFirstPostDateStruct": {"date": "2009-04-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-04-17", "resultsFirstSubmitQcDate": "2009-04-17", "resultsFirstPostDateStruct": {"date": "2009-06-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-08-17", "lastUpdatePostDateStruct": {"date": "2015-08-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study was to compare the antihypertensive efficacy of different doses of losartan compared to placebo and enalapril, in patients with supine diastolic blood pressure of 100-115 mmHg."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 576, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "Losartan 10 mg", "interventionNames": ["Drug: losartan potassium"]}, {"label": "3", "type": "EXPERIMENTAL", "description": "Losartan 25 mg", "interventionNames": ["Drug: losartan potassium"]}, {"label": "4", "type": "EXPERIMENTAL", "description": "Losartan 50 mg", "interventionNames": ["Drug: losartan potassium"]}, {"label": "5", "type": "EXPERIMENTAL", "description": "Losartan 100 mg", "interventionNames": ["Drug: losartan potassium"]}, {"label": "6", "type": "EXPERIMENTAL", "description": "Losartan 150 mg", "interventionNames": ["Drug: losartan potassium"]}, {"label": "7", "type": "ACTIVE_COMPARATOR", "description": "Enalapril 20 mg", "interventionNames": ["Drug: Enalapril"]}], "interventions": [{"type": "DRUG", "name": "losartan potassium", "description": "losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks", "armGroupLabels": ["2", "3", "4", "5", "6"], "otherNames": ["MK0954", "Cozaar"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo capsule to losartan", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Enalapril", "description": "Enalapril 20 mg oral tablet taken once daily for 8 weeks", "armGroupLabels": ["7"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8", "timeFrame": "24 hours post dose at Baseline and Week 8"}], "secondaryOutcomes": [{"measure": "Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8", "description": "Patients in Category I (defined as \"excellent\" in protocol) if SuDBP was \\<90 mmHg, Category II (defined as \"good\" in protocol) if SuDBP was \u226590 but decreased at least 10 mmHg, or Category III (defined as \"fair\" or \"inadequate\" in protocol) if SuDBP was \u226590 and decreased less than 10 mmHg.", "timeFrame": "24 hours post dose at Week 8"}, {"measure": "Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8", "timeFrame": "6 hours post dose at Baseline and 8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has been diagnosed with mild to moderate hypertension, with supine diastolic blood pressure of 100 to 115 mmHg\n* Patient has no active medical problems other than essential hypertension that might affect blood pressure\n* Patient has received no drug therapy that might affect blood pressure\n\nExclusion Criteria:\n\n* Prior exposure to losartan\n* History of stroke\n* History of myocardial infarction\n* Atrial flutter or atrial fibrillation\n* History of congestive Heart failure\n* Known Sensitivity to ACE inhibitors\n* Known positive test for HIV/AIDS or Hepatitis B\n* Patient is being treated for acute ulcer disease\n* History of chronic liver disease\n* Actively treated diabetes mellitis\n* Any known bleeding or platelet disorder\n* Absence of one kidney\n* Women of childbearing potential or who are breastfeeding\n* Patient is abusing or has a history of alcoholism or drug addiction", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "7768585", "type": "BACKGROUND", "citation": "Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995 Jun;25(6):1345-50. doi: 10.1161/01.hyp.25.6.1345."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients could be randomized after the 4-week placebo baseline period if their mean supine diastolic blood pressure (SuDBP) was 100-115 mmHg and \u22647 mmHg from the mean SuDBP after 2 weeks of placebo therapy, or after a 2-week placebo baseline period if 2 sets of SuDBP data were within 100-115 mmHg, \u22653 days apart and differed by \u22647 mmHg.", "recruitmentDetails": "Patients were recruited at 28 sites in the United States. Primary Therapy Period: December, 1990-August, 1991", "groups": [{"id": "FG000", "title": "Placebo", "description": "Losartan and Enalapril placebo orally once daily for 8 weeks"}, {"id": "FG001", "title": "Losartan 10 mg", "description": "Losartan 10 mg orally once daily for 8 weeks"}, {"id": "FG002", "title": "Losartan 25 mg", "description": "Losartan 25 mg orally once daily for 8 weeks"}, {"id": "FG003", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 8 weeks"}, {"id": "FG004", "title": "Losartan 100 mg", "description": "Losartan 100 mg orally once daily for 8 weeks"}, {"id": "FG005", "title": "Losartan 150 mg", "description": "Losartan 150 mg orally once daily for 8 weeks"}, {"id": "FG006", "title": "Enalapril 20", "description": "Enalapril 20 mg orally once daily for 8 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "78"}, {"groupId": "FG001", "numSubjects": "80"}, {"groupId": "FG002", "numSubjects": "82"}, {"groupId": "FG003", "numSubjects": "79"}, {"groupId": "FG004", "numSubjects": "90"}, {"groupId": "FG005", "numSubjects": "84"}, {"groupId": "FG006", "numSubjects": "83"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "67"}, {"groupId": "FG001", "numSubjects": "72"}, {"groupId": "FG002", "numSubjects": "75"}, {"groupId": "FG003", "numSubjects": "76"}, {"groupId": "FG004", "numSubjects": "80"}, {"groupId": "FG005", "numSubjects": "77"}, {"groupId": "FG006", "numSubjects": "79"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "10"}, {"groupId": "FG005", "numSubjects": "7"}, {"groupId": "FG006", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "4"}, {"groupId": "FG006", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "3"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "1"}]}, {"type": "Patient Uncooperative", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Losartan and Enalapril placebo orally once daily for 8 weeks"}, {"id": "BG001", "title": "Losartan 10 mg", "description": "Losartan 10 mg orally once daily for 8 weeks"}, {"id": "BG002", "title": "Losartan 25 mg", "description": "Losartan 25 mg orally once daily for 8 weeks"}, {"id": "BG003", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 8 weeks"}, {"id": "BG004", "title": "Losartan 100 mg", "description": "Losartan 100 mg orally once daily for 8 weeks"}, {"id": "BG005", "title": "Losartan 150 mg", "description": "Losartan 150 mg orally once daily for 8 weeks"}, {"id": "BG006", "title": "Enalapril 20", "description": "Enalapril 20 mg orally once daily for 8 weeks"}, {"id": "BG007", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "78"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "82"}, {"groupId": "BG003", "value": "79"}, {"groupId": "BG004", "value": "90"}, {"groupId": "BG005", "value": "84"}, {"groupId": "BG006", "value": "83"}, {"groupId": "BG007", "value": "576"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.3", "spread": "11.6"}, {"groupId": "BG001", "value": "53.9", "spread": "12.3"}, {"groupId": "BG002", "value": "52.8", "spread": "12.2"}, {"groupId": "BG003", "value": "52.8", "spread": "10.3"}, {"groupId": "BG004", "value": "54.0", "spread": "10.2"}, {"groupId": "BG005", "value": "53.9", "spread": "10.8"}, {"groupId": "BG006", "value": "51.9", "spread": "11.1"}, {"groupId": "BG007", "value": "53.1", "spread": "11.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "27"}, {"groupId": "BG003", "value": "26"}, {"groupId": "BG004", "value": "31"}, {"groupId": "BG005", "value": "22"}, {"groupId": "BG006", "value": "27"}, {"groupId": "BG007", "value": "193"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "55"}, {"groupId": "BG003", "value": "53"}, {"groupId": "BG004", "value": "59"}, {"groupId": "BG005", "value": "62"}, {"groupId": "BG006", "value": "56"}, {"groupId": "BG007", "value": "383"}]}]}]}, {"title": "Race/Ethnicity", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "57"}, {"groupId": "BG004", "value": "66"}, {"groupId": "BG005", "value": "64"}, {"groupId": "BG006", "value": "64"}, {"groupId": "BG007", "value": "438"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "17"}, {"groupId": "BG005", "value": "11"}, {"groupId": "BG006", "value": "7"}, {"groupId": "BG007", "value": "75"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "10"}, {"groupId": "BG007", "value": "59"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "2"}, {"groupId": "BG007", "value": "4"}]}]}]}, {"title": "SuDBP", "description": "Supine Diastolic Blood Pressure (SuDBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "103.3", "spread": "3.8"}, {"groupId": "BG001", "value": "104.3", "spread": "3.9"}, {"groupId": "BG002", "value": "103.3", "spread": "3.7"}, {"groupId": "BG003", "value": "104.0", "spread": "3.7"}, {"groupId": "BG004", "value": "104.1", "spread": "4.2"}, {"groupId": "BG005", "value": "103.4", "spread": "3.4"}, {"groupId": "BG006", "value": "103.1", "spread": "3.7"}, {"groupId": "BG007", "value": "103.7", "spread": "3.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8", "description": "Patients in Category I (defined as \"excellent\" in protocol) if SuDBP was \\<90 mmHg, Category II (defined as \"good\" in protocol) if SuDBP was \u226590 but decreased at least 10 mmHg, or Category III (defined as \"fair\" or \"inadequate\" in protocol) if SuDBP was \u226590 and decreased less than 10 mmHg.", "populationDescription": "An \"all patients treated\" approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "24 hours post dose at Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan and Enalapril placebo orally once daily for 8 weeks"}, {"id": "OG001", "title": "Losartan 10 mg", "description": "Losartan 10 mg orally once daily for 8 weeks"}, {"id": "OG002", "title": "Losartan 25 mg", "description": "Losartan 25 mg orally once daily for 8 weeks"}, {"id": "OG003", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 8 weeks"}, {"id": "OG004", "title": "Losartan 100 mg", "description": "Losartan 100 mg orally once daily for 8 weeks"}, {"id": "OG005", "title": "Losartan 150 mg", "description": "Losartan 150 mg orally once daily for 8 weeks"}, {"id": "OG006", "title": "Enalapril 20", "description": "Enalapril 20 mg orally once daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "80"}, {"groupId": "OG002", "value": "82"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "89"}, {"groupId": "OG005", "value": "84"}, {"groupId": "OG006", "value": "82"}]}], "classes": [{"title": "Category I", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "24"}, {"groupId": "OG004", "value": "29"}, {"groupId": "OG005", "value": "28"}, {"groupId": "OG006", "value": "35"}]}]}, {"title": "Category II", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "7"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "19"}, {"groupId": "OG005", "value": "12"}, {"groupId": "OG006", "value": "16"}]}]}, {"title": "Category III", "categories": [{"measurements": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "54"}, {"groupId": "OG003", "value": "39"}, {"groupId": "OG004", "value": "41"}, {"groupId": "OG005", "value": "44"}, {"groupId": "OG006", "value": "31"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8", "populationDescription": "The primary analysis employed an \"all patients treated\" approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "24 hours post dose at Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan and Enalapril placebo orally once daily for 8 weeks"}, {"id": "OG001", "title": "Losartan 10 mg", "description": "Losartan 10 mg orally once daily for 8 weeks"}, {"id": "OG002", "title": "Losartan 25 mg", "description": "Losartan 25 mg orally once daily for 8 weeks"}, {"id": "OG003", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 8 weeks"}, {"id": "OG004", "title": "Losartan 100 mg", "description": "Losartan 100 mg orally once daily for 8 weeks"}, {"id": "OG005", "title": "Losartan 150 mg", "description": "Losartan 150 mg orally once daily for 8 weeks"}, {"id": "OG006", "title": "Enalapril 20", "description": "Enalapril 20 mg orally once daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "80"}, {"groupId": "OG002", "value": "82"}, {"groupId": "OG003", "value": "78"}, {"groupId": "OG004", "value": "89"}, {"groupId": "OG005", "value": "84"}, {"groupId": "OG006", "value": "82"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.6", "spread": "7.8"}, {"groupId": "OG001", "value": "-7.9", "spread": "7.6"}, {"groupId": "OG002", "value": "-6.8", "spread": "7.9"}, {"groupId": "OG003", "value": "-10.1", "spread": "7.0"}, {"groupId": "OG004", "value": "-9.9", "spread": "6.9"}, {"groupId": "OG005", "value": "-9.7", "spread": "8.0"}, {"groupId": "OG006", "value": "-11.2", "spread": "6.7"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8", "populationDescription": "An \"all patients treated\" approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "6 hours post dose at Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Losartan and Enalapril placebo orally once daily for 8 weeks"}, {"id": "OG001", "title": "Losartan 10 mg", "description": "Losartan 10 mg orally once daily for 8 weeks"}, {"id": "OG002", "title": "Losartan 25 mg", "description": "Losartan 25 mg orally once daily for 8 weeks"}, {"id": "OG003", "title": "Losartan 50 mg", "description": "Losartan 50 mg orally once daily for 8 weeks"}, {"id": "OG004", "title": "Losartan 100 mg", "description": "Losartan 100 mg orally once daily for 8 weeks"}, {"id": "OG005", "title": "Losartan 150 mg", "description": "Losartan 150 mg orally once daily for 8 weeks"}, {"id": "OG006", "title": "Enalapril 20", "description": "Enalapril 20 mg orally once daily for 8 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "80"}, {"groupId": "OG003", "value": "77"}, {"groupId": "OG004", "value": "87"}, {"groupId": "OG005", "value": "81"}, {"groupId": "OG006", "value": "82"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.7", "spread": "8.7"}, {"groupId": "OG001", "value": "-7.3", "spread": "9.4"}, {"groupId": "OG002", "value": "-9.9", "spread": "8.5"}, {"groupId": "OG003", "value": "-11.9", "spread": "9.2"}, {"groupId": "OG004", "value": "-10.4", "spread": "8.9"}, {"groupId": "OG005", "value": "-13.1", "spread": "9.0"}, {"groupId": "OG006", "value": "-16.2", "spread": "10.4"}]}]}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Executive Vice President, Clinical and Quantitative Sciences", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000004656", "term": "Enalapril"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M21701", "name": "Losartan", "asFound": "Gradual", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M7822", "name": "Enalapril", "asFound": "Box", "relevance": "HIGH"}, {"id": "M18330", "name": "Enalaprilat", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}